. 2019 Mar 4;6:3. doi: 10.1186/s40673-019-0097-2

Table 1.

Mixed-ANOVA of P300 variables for SCA2 patients, preclinical carriers and healthy controls

ERP	Variable	SCA2 patients	Preclinical carriers	Healthy controls	Mixed-ANOVA
ERP	Variable	SCA2 patients	Preclinical carriers	Healthy controls	Group	Site	Group x Site
Visual	Latency
	Cz	462.80 ± 7.40***^/¶¶	421.34 ± 9.06*	384.68 ± 7.08	F = 53.73	F = 0.12	F = 0.10
	Pz	463.41 ± 7.40***^/¶¶	420.46 ± 9.92^ns	390.54 ± 8.10	p < 0.0001	p > 0.05	p > 0.05
	Amplitude
	Cz	9.23 ± 1.12**	11.63 ± 1.41^ns	15.28 ± 1.10	F = 14.00	F = 0.20	F = 0.06
	Pz	9.03 ± 1.15**	11.44 ± 1.43^ns	14.39 ± 1.09	p < 0.0001	p > 0.05	p > 0.05
Auditory	Latency
	Cz	437.91 ± 8.88***^/¶¶	380.66 ± 10.88^ns	358.05 ± 9.64	F = 41.18	F = 1.09	F = 0.61
	Pz	438.21 ± 9.79***	401.67 ± 11.79*	360.94 ± 10.76	p < 0.0001	p > 0.05	p > 0.05
	Amplitude
	Cz	9.47 ± 1.25*	12.63 ± 1.51^ns	16.99 ± 1.29	F = 9.47	F = 0.263	F = 0.03
	Pz	9.48 ± 1.11*	11.48 ± 1.33^ns	15.50 ± 1.22	p < 0.0001	p > 0.05	p > 0.05

Asterisks denote the statistical differences between SCA2 patients or preclinical carriers and controls (*:p < 0.05; **:p < 0.005; ***:p < 0.0005). Pilcrow denote the statistical differences between SCA2 patients and preclinical carriers (^¶¶: p < 0.005)